ICD-10-CM · Multi-region

M11.09

Hydroxyapatite deposition disease (HADD) involving two or more anatomically distinct joint sites simultaneously, classified under the crystal arthropathy family of diagnoses.

Verified May 8, 2026 · 5 sources ↓

Status
Billable
Chapter
13
Related CPT
9
Region
Multi-region
Drawn from CDCICD10DataAAPC

Documentation tips

What should appear in the chart to support M11.09.

Source · Editorial brief grounded in 5 cited references ↓

  • List every affected joint by name and side — 'bilateral shoulders and right hip' is sufficient to support M11.09; 'multiple joints' alone is not.
  • Specify the crystal type as hydroxyapatite (not simply 'calcific tendinitis' or 'crystal arthropathy') to justify M11.0x over M11.8x or M11.9.
  • Record imaging findings — radiographic calcification, ultrasound echogenic foci, or MRI signal changes — at each affected site to substantiate multi-site involvement.
  • Note symptom duration and acuity (acute flare vs. chronic) at each site; this supports medical necessity for procedures performed at multiple joints on the same date.
  • If a systemic or metabolic condition is suspected or confirmed as the etiology of HADD, document and code it additionally.

Related CPT procedures

Procedure codes commonly billed with M11.09. Linking the right diagnosis to the right procedure is what establishes medical necessity.

Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis

Common coding pitfalls

The recurring mistakes coders make with M11.09 and adjacent codes.

Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓

  • Using M11.09 when only one joint is affected — 'multiple sites' requires documentation of two or more anatomically distinct regions; otherwise use the single-site code.
  • Conflating HADD with CPPD: chondrocalcinosis codes (M11.1x, M11.2x) apply to calcium pyrophosphate crystals, not hydroxyapatite — the crystal type must be explicitly documented or inferable.
  • Defaulting to M11.9 (Crystal arthropathy, unspecified) when the crystal type is documented as hydroxyapatite — M11.09 is more specific and should be used.
  • Assigning M11.00 (unspecified site) when multiple sites are documented — M11.09 is the correct code for confirmed polyarticular involvement.
  • Failing to add a secondary code for an underlying metabolic condition (e.g., hyperparathyroidism E21.x, renal osteodystrophy N25.0) when the provider links HADD to a systemic cause.

Clinical context

Source · Editorial summary grounded in 5 cited references ↓

M11.09 is the correct billable code when a provider documents hydroxyapatite deposition disease affecting multiple joints — for example, bilateral shoulders plus the hip, or the shoulder and knee together. The 'multiple sites' designation is not a shortcut for unspecified laterality; it applies only when two or more distinct anatomical regions are genuinely involved and documented. If involvement is limited to a single joint region, use the site-specific code (e.g., M11.011 for right shoulder, M11.061 for right knee).

HADD occurs when calcium hydroxyapatite crystals deposit in periarticular soft tissues, tendons, or the joint itself, triggering an acute or chronic inflammatory response. The shoulder is the most commonly affected single site, but polyarticular presentations do occur. M11.09 sits within the M11.0 parent category (Hydroxyapatite deposition disease), which is distinct from chondrocalcinosis (M11.1–M11.2) and other specified crystal arthropathies (M11.8–). Do not conflate HADD with CPPD (calcium pyrophosphate deposition disease) — they are separate crystal arthropathies with separate code families.

For payers, M11.09 may support authorization for imaging (plain radiographs, ultrasound, or MRI to confirm calcific deposits at multiple sites), aspiration, corticosteroid injection, needling/barbotage, or extracorporeal shock wave therapy depending on payer policy. When a secondary metabolic condition (e.g., hyperparathyroidism, renal failure) is the underlying cause of crystal deposition, code that condition additionally per ICD-10-CM convention.

Sibling codes

Other billable codes under M11.0 (laterality / anatomic variants).

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 5 cited references ↓

01When does HADD at two shoulders qualify for M11.09 vs. two separate laterality codes?
Use M11.09 (multiple sites) when the encounter addresses both shoulders as part of a single polyarticular HADD presentation. If each shoulder is being managed as an independent, separately documented condition at different encounters, site-specific codes (M11.011, M11.012) may be more appropriate — but M11.09 is acceptable for a single encounter addressing both.
02Can M11.09 be used if the provider documents 'calcific tendinitis at multiple sites'?
Only if the calcific tendinitis is explicitly attributed to hydroxyapatite deposition disease. 'Calcific tendinitis' without crystal-type specification typically maps to M65.2x (calcific tendinitis). The provider must document HADD or hydroxyapatite crystals specifically to support M11.09.
03What distinguishes M11.09 from M11.89 (Other specified crystal arthropathies, multiple sites)?
M11.09 is specific to hydroxyapatite crystals. M11.89 applies to other specified crystal types that don't fall under gout, CPPD/chondrocalcinosis, or HADD. The documented crystal type drives the choice.
04Is a biopsy or aspiration required to code HADD, or can imaging alone support it?
ICD-10-CM does not require laboratory confirmation for code assignment — clinical diagnosis supported by imaging (characteristic radiographic calcifications) is sufficient. However, payer medical necessity criteria for procedures like needling/barbotage may require imaging documentation.
05Should a secondary code be added when HADD is linked to end-stage renal disease or hyperparathyroidism?
Yes. Per ICD-10-CM convention, code the underlying condition (e.g., E21.0 for primary hyperparathyroidism, N18.6 for end-stage renal disease) as an additional diagnosis when the provider documents it as causally related to the crystal deposition.
06Does M11.09 require a 7th-character extension?
No. M-codes in Chapter 13 do not use 7th-character extensions. The 7th-character system (A/D/S) applies to injury codes in the S- and T-code ranges, not to musculoskeletal disease codes like M11.09.

Mira AI Scribe

Mira AI Scribe captures the names and laterality of every symptomatic joint, imaging confirmation of calcific deposits at each site, crystal type (hydroxyapatite), and any associated metabolic diagnosis from the encounter note. This prevents collapse to the less-specific M11.00 (unspecified site) or M11.9 (unspecified crystal arthropathy), which can trigger payer downcoding or medical necessity denials for multi-joint procedures.

See how Mira captures M11.09 documentation

Related ICD-10 codes

Ready?

Ready to transform your orthopedic practice?

See how orthopedic practices are running documentation, billing, and operations on a single voice-first platform.

Get started for free